Our Technology

Histogen’s technology is based on the discovery that growing fibroblast cells under simulated embryonic conditions induces them to become multipotent stem cells. The environment created by Histogen’s proprietary process mimics the conditions within the womb – very low oxygen and suspension. When cultured under these conditions, the induced multipotent stem cells generate biological materials that stimulate a patient’s own stem cells to activate and regenerate tissue.

From Histogen’s single proprietary manufacturing process, two key materials are produced: 1) a soluble multipotent cell conditioned media (CCM) that is the starting material for products for hair growth, skin care and other applications, and 2) an insoluble extracellular matrix (ECM) for applications such as orthopedics, wound care and soft tissue augmentation.

Histogen’s one technology, numerous applications approach offers a continuum of product introduction opportunities, from lead aesthetic applications such as hair regrowth and skincare, to therapeutics including orthopedics and wound healing.


Key Advantages

Histogen’s novel manufacturing process offers numerous potential benefits:

None of the ethical drawbacks of embryonic stem cells, or safety concerns associated with animal-derived materials.

Histogen has successfully developed production processes which are highly scalable and economically viable.

All of the derivatives of the manufacturing process can be used, creating a spectrum of products for a variety of markets from one core technology.

Our Patents

Histogen’s first US patent was issued in September 2012, and covers the Company’s novel method of growing cells under low oxygen and suspension conditions, and the process through which the naturally-secreted protein compositions are produced. As of December 31, 2019, Histogen holds 8 issued US patents, 40 issued foreign patents and 30 active patent applications in the US and elsewhere.

  • 8,257,947

    Extracellular Matrix Compositions Produced Under Hypoxic Culture Conditions

  • 8,524,494

    Low Oxygen Tension and bFGF Generates a Multipotent Stem Cell from a Fibroblast In Vitro

  • 8,530,415

    Repair and/or Regeneration of Cells with a Composition Produced by Culturing Fibroblast Cells under Hypoxic Conditions

  • 8,535,913

    Soluble Composition for Promoting Hair Growth Produced by Hypoxic Culture of Fibroblast Cells

  • 8,852,637

    Extracellular Matrix Compositions for the Treatment of Cancer

  • 9,034,312

    Extracellular Matrix Compositions for the Treatment of Cancer

  • 9,506,038

    Extracellular Matrix Compositions for the Treatment of Cancer

  • 9,512,403

    Conditioned Medium and Extracellular Matrix Compositions from Cells Cultured under Hypoxic Conditions for Methods of Treating Tissue Injury

  • Development Pipeline